跳至主要内容

Medicilon was awarded the "Industry Outstanding Member Unit Management Award" by the China Laboratory Primate Breeding and Development Association

 Recently, the China Laboratory Primate Breeding and Development Association Industry Academic Exchange Conference and 30th Anniversary Celebration were held as scheduled at the Dragon Lake Princess Hotel in Huadu, Guangzhou.  As a member, Shanghai Medicilon Inc. was invited to attend the conference and was awarded the "Industry Outstanding Member Unit Management Award".

Nonhuman primate research is an indispensable part of preclinical research and plays a link between basic research and clinical trial.  As a one-stop biopharmaceutical preclinical R&D service platform in China, Medicilon established a "non-human primate professional technical service platform" as early as 2008.  After nearly 16 years of experience and technology accumulation, the non-human primate professional technical service platform has established mature models in the fields of ophthalmic diseases, inflammatory and autoimmune diseases, endocrine, metabolic diseases and more.  Medicilon can provide pharmacodynamics, pharmacokinetics and safety evaluation tests in compliance with international and China GLP specifications, international AAALAC requirements, FDA standards and ICH requirements, providing strong support for promoting clinical development.

Industry Outstanding Member Unit Management Award.webp

It is worth mentioning that Medicilon's "Professional Technical Service Platform for Non-Human Primates" has been selected into the Shanghai International Services Trade Demonstration Project.  At present, Medicilon has complete animal models such as mice, rats, rabbits, pigs, dogs, and monkeys, which can meet clients' different types of new drug research and development needs.  Among them, the non-human primate experimental facility is the largest laboratory in Shanghai with the largest number of monkeys.

Medicilon respects the life of experimental animals, pays attention to the welfare ethics of experimental animals, and actively implements the "3Rs" principles of use of experimental animals and the "Five Basic Welfare", providing different toys, sports facilities, nutritious fruits, play light music and cartoons for different species of experimental animals to ensure that the animals are in a comfortable, healthy, happy and natural living state.

In the future, Medicilon will maintain and protect the welfare of experimental animals, cherish every experimental opportunity, provide high-quality and efficient scientific research services for global new drug research and development, and empower the innovative development of life sciences.

PS: We would like to express our highest respect to all experimental animals that devote themselves to life sciences!

标签：

评论

发表评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文